EGFR and non-small cell lung carcinoma: With recent evidence showing that 10–30% of the NSCLC patients present “actionable” mutations of Epidermal Growth Factor Receptor (EGFR) (3), tremendous advances have been made in the treatment of these patients in recent years, by directly targeting these specific mutations (4).